Author pages are created from data sourced from our academic publisher partnerships and public sources.
Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours.
- V. Zamora, A. Cabanne, +7 authors E. Roca
- Digestive and liver disease : official journal of…
- 1 March 2010
INTRODUCTION Somatostatin receptors are expressed in a large number of human tumours. The somatostatin receptors types 1-5 expression in a series including 100 gastro-entero-pancreatic endocrine… Expand
Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study.
- J. O’connor, F. Marmissolle, +24 authors E. Roca
- Molecular and clinical oncology
- 1 September 2014
Neuroendocrine tumors (NET) include a spectrum of malignancies arising from neuroendocrine cells throughout the body. The objective of this clinical investigation of retrospectively and prospectively… Expand
Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
- S. Belli, A. Oneto, +8 authors F. Marmissolle
- Acta gastroenterologica Latinoamericana
- 1 September 2009
Elevated circulating levels of chromogranin A (CgA) are found in the neuroendocrine tumors (NETs), but diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the… Expand
Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
Neuroendocrine tumors and CUP
ABSTRACT Background RADIANT-3 was a phase III study investigating the effect of the mammalian target of rapamycin inhibitor everolimus on progression-free survival (PFS) in patients with advanced… Expand
Neuroendocrine tumors of the gastroenteropancreatic system (NET-GEP). Correlation between Ki-67 immunostaining, histological features and clinical behaviour
Correlation between IHC and FISH for HER2/neu assessment in patients with breast cancer
Paclitaxel and cisplatin in stage IV non-small cell lung cancer: A GETICS phase II study
Somatostatin receptor (SSTR) expression and proliferative index (Ki 67) in 100 patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Clinical-pathological correlation.
e14598 Background: Somatostatin receptor expression (SSTR), mainly subtypes 2 and 5, is a feature of well differentiated GEP-NETs. Such expression has a prognostic and predictive value for the use of… Expand